Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BerGenBio ASA ( (BRRGF) ) has issued an announcement.
BerGenBio ASA has announced the approval of a prospectus by the Financial Supervisory Authority of Norway for its merger with Oncoinvent ASA and a subsequent rights issue to raise NOK 130 million. This strategic move is expected to enhance the company’s market position by expanding its shareholder base and securing additional capital for its operations, with trading of new shares anticipated to commence shortly on the Oslo Stock Exchange.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA is a biotechnology company focused on developing innovative drugs for aggressive diseases, particularly in the field of oncology. The company is involved in the research and development of therapeutics aimed at targeting the AXL receptor tyrosine kinase, which is implicated in cancer progression and immune suppression.
Average Trading Volume: 82,805
Current Market Cap: NOK45.18M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.